Long-term Survival of Esophageal Squamous Cell Carcinoma after Surgical Treatment in a Large-Scale Retrospective Study from a Single Cancer Center
Kunhan Ni,Zhiyu Li,Kexun Li,Changding Li,Kunyi Du,Xin Nie,Kun Liu,Kunzhi Li,Yixuan Huang,Simiao Lu,Longlin Jiang,Wenwu He,Chenghao Wang,Kangning Wang,Qiang Zhou,Haojun Li,Jialong Li,Guangyuan Liu,Wenguang Xiao,Qiang Fang,Lin Peng,Qifeng Wang,Yongtao Han,Xuefeng Leng
DOI: https://doi.org/10.1007/s44178-023-00049-6
2023-01-01
Holistic Integrative Oncology
Abstract:Purpose To analyze the long-term overall survival (OS) and influencing factors of patients with esophageal squamous cell cancer (ESCC) under surgical treatment. Method We collected patients with ESCC who received surgical treatment in Sichuan Cancer Hospital & institute from January 2010 to December 2017, and selected 2,766 patients with thoracic esophageal carcinoma with relatively complete follow-up results as the objects of this study. We analyzed the characteristics, postoperative complications and long-term OS results of those patients. Results Of the 2766 patients, 81.6% were male, midthoracic esophageal cancer accounted for 53.5%. McKeown was used in 72.0% of patients and Ivor-Lewis was used in 26.4% of patients. About 47.8% of patients received minimally invasive esophagectomy (MIE). The overall complication rate was 25.8%. The 1-year, 3-year and 5-year OS rates were 86.2%, 57.5% and 46.8%, respectively. McKeown had a better long-term OS rate than Ivor-Lewis (49.5% vs 41.2%, P < 0.001), and MIE is superior to open surgery (51.8% vs 42.5%, P < 0.001). Conclusion McKeown has advantages over Ivor-Lewis. MIE results in better long-term survival outcomes for patients. But more prospective randomized controlled trials with large samples are needed.